Chris Pollard - Concepedia

Author

Chris Pollard

AstraZeneca (United Kingdom)

Also Known As

CHRIS POLLARD, Chris E Pollard, Chris E. Pollard, Chris Pollard

Publications

846

Citations

H-Index

Concepts

All Affiliations

AstraZeneca (United Kingdom)AstraZeneca (Sweden)AstraZeneca (United States)

About

Chris Pollard is an author at AstraZeneca (United Kingdom) specializing in medicine, pharmacology, and electrophysiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	236
2	Social Sciences	2	2	124
3	Neuroscience	2	2	124
4	Anatomy	1	1	45
5	Kinesiology	1	1	45

Chris Pollard

Publications

474

Citations

H-Index

Page 1

	Year	Citations
A framework to assess the translation of safety pharmacology data to humans Jean‐Pierre Valentin, Russell Bialecki, Lorna Ewart, Journal of Pharmacological and Toxicological Methods Drug SafetyTranslational MedicinePreclinical Drug EvaluationPatient SafetyPharmacology	2009	94
IKs restricts excessive beat-to-beat variability of repolarization during beta-adrenergic receptor stimulation Daniel M. Johnson, Jordi Heijman, Chris Pollard, Journal of Molecular and Cellular Cardiology Beta-adrenergic Receptor StimulationAdrenal GlandHyperpolarization (Biology)Excessive Beat-to-beat VariabilityNeurophysiology	2009	79
Comparative Pharmacology of Guinea Pig Cardiac Myocyte and Cloned hERG (I<sub>Kr</sub>) Channel Christina Savanthi. Davie, JEAN PIERRE‐VALENTIN, Chris Pollard, Journal of Cardiovascular Electrophysiology	2004	69
Dog left ventricular midmyocardial myocytes for assessment of drug‐induced delayed repolarization: short‐term variability and proarrhythmic potential Najah Abi‐Gerges, Jean‐Pierre Valentin, Chris Pollard British Journal of Pharmacology	2009	45
Evidence for gender differences in electrophysiological properties of canine Purkinje fibres Najah Abi‐Gerges, Ben G. Small, Tim Hammond, British Journal of Pharmacology Cardiac MuscleHeart FailureAnatomySensory SystemsSocial Sciences	2004	45
Translational pharmacokinetic–pharmacodynamic modeling of QTc effects in dog and human Joanna Parkinson, Sandra A. G. Visser, Philip Jarvis, Journal of Pharmacological and Toxicological Methods Translational MedicineQtc EffectsPharmacokinetic ModelingPharmacological StudyMedicine	2013	39
Impact and prevalence of safety pharmacology-related toxicities throughout the pharmaceutical life cycle Will S. Redfern, Russ Bialecki, Lorna Ewart, Journal of Pharmacological and Toxicological Methods Drug SafetySafety Pharmacology-related ToxicitiesPatient SafetyPharmacologyPharmacological Issue	2010	33
Gender differences in the slow delayed (<i>I</i><sub>Ks</sub>) but not in inward (<i>I</i><sub>K1</sub>) rectifier K<sup>+</sup>currents of canine Purkinje fibre cardiac action potential: key roles for<i>I</i><sub>Ks</sub>,<i>β</i>‐adrenoceptor stimulation, pacing rate and gender Najah Abi‐Gerges, Ben G. Small, Tim Hammond, British Journal of Pharmacology	2005	31
Validation of a voltage-sensitive dye (di-4-ANEPPS)-based method for assessing drug-induced delayed repolarisation in Beagle dog left ventricular midmyocardial myocytes M Hardy, Chris Pollard, Ben G. Small, Journal of Pharmacological and Toxicological Methods Cardiac MuscleHeart FailureVoltage-sensitive DyeMedicinePhysiology	2009	25
Prediction and Modeling of Effects on the QTc Interval for Clinical Safety Margin Assessment, Based on Single-Ascending-Dose Study Data with AZD3839 Erik Sparve, Angelica Quartino, Maria Lüttgen, Journal of Pharmacology and Experimental Therapeutics	2014	14

Page 1